Vopimetostat-daraxonrasib combo ‘extremely encouraging’ in metastatic pancreatic cancer

A two-drug combination exhibited durable clinical benefit as second- or third-line treatment for pancreatic cancer, according to a topline data announcement released by one of the agent’s manufacturers.A vast majority of patients with methylthioadenosine phosphorylase (MTAP)-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC) responded to treatment with vopimetostat